title: Helicobacter pylori eradication with dual and low-dose triple therapy in patients with liver cirrhosis.
abstract: OBJECTIVE
  Few data exist on the treatment of Helicobacter pylori infection in cirrhotic patients. In this study we assessed the efficacy of standard dual and one-week low-dose triple therapy on Helicobacter pylori eradication in cirrhotics.
  
  
  METHODS
  In a prospective study, 83 cirrhotic patients with epigastric pain were randomised to receive either a two-week course of dual therapy, composed of omeprazole 20 mg b.d. plus amoxycillin 1 g b.d. (n = 41) or a one-week course of triple therapy, composed of omeprazole 20 mg b.d., clarithromycin 250 mg b.d., and tetracycline 500 mg b.d (n = 42). Helicobacter pylori infection at entry and eradication 6-8 weeks after the end of therapy were assessed by rapid urease test and histology on biopsies from the antrum and corpus. When eradication did not occur with either dual or triple therapy, patients were given the alternative regimen. Helicobacter pylori eradication in these patients was assessed 6-8 weeks after the end of treatment by a further endoscopy.
  
  
  RESULTS
  Helicobacter pylori eradication was achieved in 87.8% (36 out of 41; 95% confidence interval 77.8-97.8%) of patients after dual therapy and in 85.7% (36 out of 42; 95% confidence interval 75.1-96.3%) of patients treated with triple therapy (p = NS). In patients in whom initial eradication was unsuccessful, re-treatment eradicated Helicobacter pylori in 4 out of 5 patients given the triple regimen and in all 5 patients who received the dual therapy. One patient was lost to follow-up. No major side-effects were reported for either treatment regimen.
  
  
  CONCLUSIONS
  Our data show that both dual and triple therapies are effective in Helicobacter pylori eradication in cirrhotics as well as in eradication failure patients. Therefore, the use of the dual therapy regimen is strongly suggested as an initial treatment for Helicobacter pylori eradication in cirrhotic patients.
authors.affiliation: Department of Clinical Medicine-Gastroenterology, La Sapienza University, Rome, Italy. zullo@tiscalinet.it
authors.forename: A
authors.initials: A
authors.lastname: Zullo
authors.forename: V
authors.initials: V
authors.lastname: Rinaldi
authors.forename: P
authors.initials: P
authors.lastname: Meddi
authors.forename: S
authors.initials: S
authors.lastname: Winn
authors.forename: R
authors.initials: R
authors.lastname: Moscatelli
authors.forename: A F
authors.initials: AF
authors.lastname: Attili
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D016481:Helicobacter Infections / Q000150:complications* / Q000209:etiology*; D016480:Helicobacter pylori; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D011446:Prospective Studies
chemical_list: D000658:Amoxicillin; D009853:Omeprazole